Jaswinder Singh MD
Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer
Sarah Cannon Cancer Center
Join to View Full Profile
2316 E Meyer Blvd# 1Kansas City, MO 64132
Phone+1 816-276-4700
Fax+1 816-276-3810
Dr. Singh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008
Icahn School of Medicine at Mount Sinai/NYC Health and Hospitals (Elmhurst)Residency, Internal Medicine, 1999 - 2002
Government Medical College ChandigrahClass of 1997
Certifications & Licensure
MO State Medical License 2002 - 2026
KS State Medical License 2005 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Asco
Clinical Trials
- Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsEfficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenoca...E Gabriela Chiorean, Vincent Picozzi, Chung-Pin Li, Marc Peeters, Joan Maurel
Cancer Medicine. 2023-10-01 - 9 citationsDesmoid type fibromatosis: A case report with an unusual etiology.Syed Faisal Jafri, Obada Obaisi, Gerardo G Vergara, Joe Cates, Jaswinder Singh
World Journal of Gastrointestinal Oncology. 2017-09-15 - 30 citationsTreatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab ...Johanna C. Bendell, Thomas J. Ervin, David Gallinson, Jaswinder Singh, James A. Wallace
Clinical Colorectal Cancer. 2013-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
